Press news Biocartis Group: Results of the Special Shareholders’ Meeting held on 27 September 2019

NEXT STORY
Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, France
PREV STORY
Bone Therapeutics to present data from its Phase II/III trial with JTA-004 at the 2nd World Congress on Rheumatology & Orthopedics
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FIT Biotech Oy: FIT Biotech Oy’s Board of Directors has decided on the issue of Convertible Notes and Warrants

FIT Biotech Oy Company release February 14, 2018 at 5:45 pm EET FIT Biotech ...

author_avatar
NASDAQ Market News

Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update

author_avatar
NASDAQ Market News

Athenex to Host Conference Call with Key Opinion Leader Following Oral Presentation of Phase III Results of KX2-391 Ointment in the Treatment of Actinic Keratosis at the American Academy of Dermatology Annual Meeting

author_avatar
NASDAQ Market News